SecBot SecBot

Better Mental Health Care, Lower-Cost Drugs, and Extenders Act of 2023

S. 3430 Sen. Ron Wyden (D-OR) In committee
  1. Introduced Dec 7
  2. Committee Dec 7
  3. Passed Senate Next
  4. Passed House Not yet
  5. To President Not yet
  6. Law Not yet
Where it stands
In committee, Dec 7, 2023Next: Senate vote
1056d ago Dec 7, 2023: Placed on Senate Legislative Calendar under General Orders. Calendar No. 265.
Final votes
No roll callsNo recorded vote on this bill yet
Lobbying
5companies, 5 filings
Member trades
15trades in the last 90 days
Who backs the bill and who pushes back Subscribe

Companies lobbying on this bill

5 companies
Companies by sector
Biotech & Pharma 3Consumer & Retail 2
Search all 5 companies, their asks and price moves Subscribe

Summary

This bill amends the Social Security Act to expand the mental health care workforce and services under Medicare and Medicaid, reduce prescription drug costs, and extend certain expiring Medicare and Medicaid provisions.

TITLE I, Expanding mental health care workforce and services under Medicare and Medicaid: This title expands eligibility for Medicare bonus payments to mental health and substance use disorder practitioners in shortage areas, improves access to mental health services (including clinical social worker services in skilled nursing facilities), clarifies occupational therapy coverage for mental health, creates Medicare incentives for behavioral health integration with primary care for 2026-2028, establishes a telehealth modifier for mental health services, and requires guidance on telehealth for limited English proficiency patients, interstate licensure, and accessibility for the visually and hearing impaired. It also requires accurate Medicare provider directories, and directs HHS to issue guidance to states on increasing mental health provider capacity, supporting children's mental health, integrating care with primary care, and analyzing Medicaid mental health data. It creates a state option to provide Medicaid to certain inmates with substance use disorder pending charges, and defines certified community behavioral health clinic services under Medicaid.

TITLE II, Reducing prescription drug costs under Medicare and Medicaid: This title requires Medicare Part D plans to accept any willing pharmacy meeting standard contract terms starting in 2028, mandates HHS surveys to determine accurate pharmacy acquisition costs for Medicaid, and ties Medicare Part D cost-sharing for certain drugs to their net price starting in 2028.

TITLE III, Medicaid expiring provisions: This title delays certain Medicaid disproportionate share hospital payment reductions to fiscal years 2026 and 2027, and makes permanent the state option to provide medical assistance for certain individuals in institutions for mental diseases.

TITLE IV, Medicare expiring provisions and provider payment changes: This title extends funding for quality measure endorsement, low-income program outreach, the work geographic index floor, and incentive payments for alternative payment models. It delays certain durable medical equipment payment changes, extends the Independence at Home demonstration program, increases support for physicians adjusting to payment changes, revises the phase-in of clinical laboratory test payment changes, and extends the adjustment to the hospice cap calculation.

TITLE V, Offsets: This title reduces the amount in the Medicaid Improvement Fund and increases the amount in the Medicare Improvement Fund.

Summary of the bill text as reported to Senate (Dec 7, 2023), generated by SecBot from the official bill text; the Library of Congress summary is not yet published.

Official record from Congress.gov, the House Clerk and the Senate; lobbying from Lobbying Disclosure Act filings. Updated Oct 28, 2026.